Module 4 Nonclinical Study Reports: Organising the Evidence Behind the Overview

Module 4 holds the nonclinical study reports that support the safety of a medicine before and alongside clinical use. Its structure is fixed by ICH M4S, but whether assessors can follow the evidence depends on how completely and consistently the reports are organised and summarised.

The structure of Module 4

  • 4.2.1 Pharmacology: primary and secondary pharmacodynamics, safety pharmacology and pharmacodynamic drug interactions.
  • 4.2.2 Pharmacokinetics: analytical methods, absorption, distribution, metabolism, excretion and pharmacokinetic interactions.
  • 4.2.3 Toxicology: single- and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, local tolerance and other studies such as immunotoxicity or impurity qualification.
  • 4.3 Literature references.

The nonclinical overview (2.4) and the written and tabulated summaries (2.6) interpret these reports and must reference them precisely.

GLP and study quality

Pivotal nonclinical safety studies are expected to be conducted in compliance with Good Laboratory Practice, as required in the EU under Directive 2004/10/EC. Each report should include the GLP compliance statement and quality assurance statement. Where a study was not GLP-compliant, the dossier should say so and explain why its results can still be relied upon.

Timing and the ICH safety guidelines

ICH M3(R2) links the timing of nonclinical studies to the stage of clinical development, while the ICH S-series sets the design of specific study types, from safety pharmacology to genotoxicity, carcinogenicity and reproductive toxicity. Biotechnology-derived products follow the tailored approach of ICH S6(R1), where species selection and relevance carry particular weight. Gaps against these guidelines should be justified, not left for the assessor to find.

Practical points for compilation

  • Place each report in the correct subsection; misfiled studies are hard for assessors to find.
  • Make sure study numbers and titles match across Modules 2 and 4.
  • Include amendments and validation reports for bioanalytical methods.
  • For generic, hybrid or well-established use applications, explain clearly why literature or reference product data replace new studies.
  • Under the 3Rs principle reflected in Directive 2010/63/EU, avoid repeating animal studies where existing data or validated alternatives suffice.

How PQRA helps

PQRA organises and reviews Module 4 content, checks consistency with the nonclinical overview and summaries, and identifies gaps against ICH expectations before submission.

Contact PQRA to discuss your next dossier.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *